See more : Chongqing Department Store Co.,Ltd. (600729.SS) Income Statement Analysis – Financial Results
Complete financial analysis of TME Pharma N.V. (ALTME.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TME Pharma N.V., a leading company in the Biotechnology industry within the Healthcare sector.
- TDb Split Corp. (XTD.TO) Income Statement Analysis – Financial Results
- BigBen Interactive (0O0E.L) Income Statement Analysis – Financial Results
- Meitu, Inc. (1357.HK) Income Statement Analysis – Financial Results
- Contact Gold Corp. (C.V) Income Statement Analysis – Financial Results
- ESS Tech, Inc. WT (GWH-WT) Income Statement Analysis – Financial Results
TME Pharma N.V. (ALTME.PA)
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.00K | 0.00 | 33.00 | 35.00 | 154.00 | 0.00 | 234.00K | 83.00K | 43.00K | 25.00K |
| Cost of Revenue | 144.00K | 92.00K | 66.00K | 63.00K | 1.03M | 982.00K | 959.00K | 1.46M | 2.64M | 3.68M |
| Gross Profit | -127.00K | -92.00K | -65.97K | -62.97K | -1.03M | -982.00K | -725.00K | -1.38M | -2.60M | -3.65M |
| Gross Profit Ratio | -747.06% | 0.00% | -199,900.00% | -179,900.00% | -668,081.82% | 0.00% | -309.83% | -1,657.83% | -6,044.19% | -14,612.00% |
| Research & Development | 2.65M | 8.15M | 10.66M | 4.02M | 496.00K | 479.00K | 402.00K | 1.03M | 906.00K | 1.50M |
| General & Administrative | 2.99M | 1.93M | 1.27M | 912.00K | 1.32M | 1.29M | 1.13M | 2.30M | 4.97M | 1.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 263.00K | 307.00K | 409.00K | 149.00K |
| SG&A | 2.99M | 1.93M | 1.27M | 912.00K | 1.32M | 1.29M | 1.40M | 2.60M | 5.38M | 1.56M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 389.00K | 33.00K | 0.00 |
| Operating Expenses | 5.50M | 12.00M | 13.45M | 5.75M | 2.92M | 3.34M | 3.77M | 7.03M | 11.68M | 9.50M |
| Cost & Expenses | 5.64M | 12.00M | 13.45M | 5.75M | 3.94M | 4.32M | 4.73M | 8.49M | 14.32M | 13.18M |
| Interest Income | 399.00K | 303.00K | 319.00K | 418.00K | 3.09M | 388.00K | 1.02M | 1.00K | 0.00 | 3.00K |
| Interest Expense | 1.52M | 3.40M | 1.50M | 5.06M | 3.00K | 6.76M | 1.68M | 2.13M | 1.29M | 632.00K |
| Depreciation & Amortization | 144.00K | 92.00K | 66.00K | 63.00K | 47.00K | 23.00K | 29.00K | 163.00K | 218.00K | 279.00K |
| EBITDA | -5.07M | -11.63M | -12.88M | -5.29M | -810.00K | -3.96M | -3.68M | -8.44M | -14.61M | -12.88M |
| EBITDA Ratio | -29,835.29% | 0.00% | -39,036,363.64% | -15,108,571.43% | -525,974.03% | 0.00% | -1,573.50% | -9,733.73% | -32,795.35% | -51,536.00% |
| Operating Income | -5.62M | -12.03M | -13.27M | -5.77M | -3.95M | -4.37M | -4.73M | -8.60M | -14.83M | -13.17M |
| Operating Income Ratio | -33,082.35% | 0.00% | -40,203,030.30% | -16,482,857.14% | -2,563,636.36% | 0.00% | -2,021.37% | -10,360.24% | -34,488.37% | -52,664.00% |
| Total Other Income/Expenses | -1.11M | -3.10M | -1.19M | -4.64M | 3.09M | -6.37M | -659.00K | -2.31M | -1.29M | -572.00K |
| Income Before Tax | -6.73M | -15.13M | -14.45M | -10.41M | -860.00K | -10.74M | -5.39M | -10.73M | -16.12M | -13.80M |
| Income Before Tax Ratio | -39,611.76% | 0.00% | -43,793,939.39% | -29,731,428.57% | -558,441.56% | 0.00% | -2,302.99% | -12,921.69% | -37,497.67% | -55,180.00% |
| Income Tax Expense | 2.00K | 7.00K | 1.00K | 417.00K | 1.00K | 1.00K | 1.00K | 27.00K | -22.00K | 3.00K |
| Net Income | -6.74M | -15.13M | -14.45M | -10.41M | -861.00K | -10.73M | -5.39M | -10.75M | -16.10M | -13.80M |
| Net Income Ratio | -39,623.53% | 0.00% | -43,793,939.39% | -29,728,571.43% | -559,090.91% | 0.00% | -2,301.28% | -12,948.19% | -37,446.51% | -55,192.00% |
| EPS | -1.34 | -11.66 | -19.85 | -29.15 | -6.99 | -269.77 | -253.59 | -670.77 | -802.97 | -688.08 |
| EPS Diluted | -1.34 | -11.66 | -19.85 | -29.15 | -6.99 | -269.77 | -253.59 | -670.77 | -802.97 | -688.08 |
| Weighted Avg Shares Out | 5.02M | 1.30M | 727.94K | 356.98K | 123.10K | 39.79K | 21.24K | 16.02K | 20.05K | 20.05K |
| Weighted Avg Shares Out (Dil) | 5.02M | 1.30M | 727.94K | 356.98K | 123.10K | 39.79K | 21.24K | 16.02K | 20.05K | 20.05K |
Source: https://incomestatements.info
Category: Stock Reports